First Time Loading...

BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 87.73 USD -1.23% Market Closed
Updated: May 1, 2024

Intrinsic Value

BNTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. [ Read More ]

The intrinsic value of one BNTX stock under the Base Case scenario is 46.71 USD. Compared to the current market price of 87.73 USD, BioNTech SE is Overvalued by 47%.

Key Points:
BNTX Intrinsic Value
Base Case
46.71 USD
Overvaluation 47%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
BioNTech SE

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BNTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
BioNTech SE

Provide an overview of the primary business activities
of BioNTech SE.

What unique competitive advantages
does BioNTech SE hold over its rivals?

What risks and challenges
does BioNTech SE face in the near future?

Summarize the latest earnings call
of BioNTech SE.

What significant events have occurred
in BioNTech SE over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for BioNTech SE.

Provide P/S
for BioNTech SE.

Provide P/E
for BioNTech SE.

Provide P/OCF
for BioNTech SE.

Provide P/FCFE
for BioNTech SE.

Provide P/B
for BioNTech SE.

Provide EV/S
for BioNTech SE.

Provide EV/GP
for BioNTech SE.

Provide EV/EBITDA
for BioNTech SE.

Provide EV/EBIT
for BioNTech SE.

Provide EV/OCF
for BioNTech SE.

Provide EV/FCFF
for BioNTech SE.

Provide EV/IC
for BioNTech SE.

Show me price targets
for BioNTech SE made by professional analysts.

What are the Revenue projections
for BioNTech SE?

How accurate were the past Revenue estimates
for BioNTech SE?

What are the Net Income projections
for BioNTech SE?

How accurate were the past Net Income estimates
for BioNTech SE?

What are the EPS projections
for BioNTech SE?

How accurate were the past EPS estimates
for BioNTech SE?

What are the EBIT projections
for BioNTech SE?

How accurate were the past EBIT estimates
for BioNTech SE?

Compare the revenue forecasts
for BioNTech SE with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of BioNTech SE and its key competitors using the latest financial data.

Compare historical revenue growth rates
of BioNTech SE against its competitors.

Analyze the profit margins
(gross, operating, and net) of BioNTech SE compared to its peers.

Compare the P/E ratios
of BioNTech SE against its peers.

Discuss the investment returns and shareholder value creation
comparing BioNTech SE with its peers.

Analyze the financial leverage
of BioNTech SE compared to its main competitors.

Show all profitability ratios
for BioNTech SE.

Provide ROE
for BioNTech SE.

Provide ROA
for BioNTech SE.

Provide ROIC
for BioNTech SE.

Provide ROCE
for BioNTech SE.

Provide Gross Margin
for BioNTech SE.

Provide Operating Margin
for BioNTech SE.

Provide Net Margin
for BioNTech SE.

Provide FCF Margin
for BioNTech SE.

Show all solvency ratios
for BioNTech SE.

Provide D/E Ratio
for BioNTech SE.

Provide D/A Ratio
for BioNTech SE.

Provide Interest Coverage Ratio
for BioNTech SE.

Provide Altman Z-Score Ratio
for BioNTech SE.

Provide Quick Ratio
for BioNTech SE.

Provide Current Ratio
for BioNTech SE.

Provide Cash Ratio
for BioNTech SE.

What is the historical Revenue growth
over the last 5 years for BioNTech SE?

What is the historical Net Income growth
over the last 5 years for BioNTech SE?

What is the current Free Cash Flow
of BioNTech SE?

Discuss the annual earnings per share (EPS)
trend over the past five years for BioNTech SE.

Financials

Balance Sheet Decomposition
BioNTech SE

Current Assets 19.5B
Cash & Short-Term Investments 16.5B
Receivables 2.3B
Other Current Assets 638.6m
Non-Current Assets 3.5B
Long-Term Investments 1.2B
PP&E 971.6m
Intangibles 1.2B
Other Non-Current Assets 164.7m
Current Liabilities 2.1B
Accounts Payable 354m
Other Current Liabilities 1.7B
Non-Current Liabilities 689.9m
Long-Term Debt 191m
Other Non-Current Liabilities 498.9m
Efficiency

Earnings Waterfall
BioNTech SE

Revenue
3.8B EUR
Cost of Revenue
-599.8m EUR
Gross Profit
3.2B EUR
Operating Expenses
-2.3B EUR
Operating Income
908m EUR
Other Expenses
22.3m EUR
Net Income
930.3m EUR

Free Cash Flow Analysis
BioNTech SE

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BNTX Profitability Score
Profitability Due Diligence

BioNTech SE's profitability score is 76/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Exceptional 3-Years Revenue Growth
76/100
Profitability
Score

BioNTech SE's profitability score is 76/100. The higher the profitability score, the more profitable the company is.

BNTX Solvency Score
Solvency Due Diligence

BioNTech SE's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

BioNTech SE's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BNTX Price Targets Summary
BioNTech SE

Wall Street analysts forecast BNTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BNTX is 121.72 USD with a low forecast of 90.9 USD and a high forecast of 179.55 USD.

Lowest
Price Target
90.9 USD
4% Upside
Average
Price Target
121.72 USD
39% Upside
Highest
Price Target
179.55 USD
105% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

BNTX Price
BioNTech SE

1M 1M
-6%
6M 6M
-6%
1Y 1Y
-22%
3Y 3Y
-57%
5Y 5Y
+524%
10Y 10Y
+524%
Annual Price Range
87.73
52w Low
86.17
52w High
125.08
Price Metrics
Average Annual Return 107.13%
Standard Deviation of Annual Returns 97.42%
Max Drawdown -80%
Shares Statistics
Market Capitalization 20.9B USD
Shares Outstanding 241 874 900
Percentage of Shares Shorted 6.17%

BNTX Return Decomposition
Main factors of price return

What is price return decomposition?

BNTX News

Other Videos

Last Important Events
BioNTech SE

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
BioNTech SE

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

BioNTech SE Logo
BioNTech SE

Country

Germany

Industry

Biotechnology

Market Cap

20.9B USD

Dividend Yield

0%

Description

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 3,082 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The company develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Contact

RHEINLAND-PFALZ
Mainz
An der Goldgrube 12
+4949613190840.0
https://biontech.de/

IPO

2019-10-10

Employees

3 082

Officers

Co-Founder, CEO & Chair of the Management Board
Dr. Ugur Sahin M.D.
Co-Founder, Chief Medical Officer & Member of Management Board
Dr. Ozlem Tureci M.D.
CFO & Member of Management Board
Mr. Jens H. Holstein
MD, COO & Member of Management Board
Dr. Sierk Poetting Ph.D.
Chief Strategy Officer, MD & Member of Management Board
Mr. Ryan Richardson
Chief Business Officer, Chief Commercial Officer & Member of Management Board
Mr. Sean Marett
Show More
Chief Legal Officer & Member of the Management Board
Dr. James Timothy Patrick Ryan Ph.D.
Senior Vice President of Corporate Development & Strategy
Mr. Zach Taylor
Senior VP & External Consultant for RNA Protein Replacement Therapies
Dr. Katalin Kariko Ph.D.
Senior Vice President of Operations
Dr. Oliver Henning Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one BNTX stock?

The intrinsic value of one BNTX stock under the Base Case scenario is 46.71 USD.

Is BNTX stock undervalued or overvalued?

Compared to the current market price of 87.73 USD, BioNTech SE is Overvalued by 47%.